Zydus Lifesciences Ltd.

ZYDUSLIFE

₹889.65

0.72% (6.35)

Market Cap

₹89,530 Cr.

P/E

19.78

About

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), a Company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with busine… Read more

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), a Company limited by… Read more

Low

795

52W Range

High

1324

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	3,748	5,755	6,483	12,164	12,231	12,133	12,189	11,521	12,369	13,134
Shareholders Funds	5,699	6,960	8,745	10,386	10,376	12,992	17,000	17,516	19,830	23,953
Profit & Loss
Operating Profit	2,330	1,904	2,847	2,978	2,780	3,385	3,175	3,572	5,299	7,013
Net Sales	9,427	9,377	11,905	13,166	14,253	14,404	15,110	17,237	19,547	23,242
Cash flow
Cash from Operating Activity	1,894	1,312	919	1,282	2,932	3,294	2,105	2,689	3,228	6,777
Net Capex (est)	957	2,935	1,035	1,046	889	847	1,055	992	883	1,661
Ratios
ROCE (%)	32.78	18.60	22.06	17.06	15.11	18.67	15.11	17.52	22.00	—
ROE (%)	33.93	21.38	20.31	17.80	11.34	16.42	26.40	11.19	19.46	—

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

1.08 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

3.46 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

18.14 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

0.34 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

95.40 %

(as of Dec 24)

Source/Historic

Artificial Sweetener Market Share (Sugar Free Natura)

0.16 %

(as of Nov 21)

Historic

Blood Related - Market Share

4.73 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

4.10 %

(as of Dec 24)

Source/Historic

Complan

3.51 %

(as of Nov 21)

Historic

Dermatology - Market Share

9.08 %

(as of Nov 21)

Historic

Endocrinology - Market Share

47.30 %

(as of Dec 24)

Source/Historic

Face Wash Market Share

3.54 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

58.90 %

(as of Dec 24)

Source/Historic

Glucon-D

3.89 %

(as of Nov 21)

Historic

Gynecology - Market Share

0.63 %

(as of Nov 21)

Historic

Neurological - Market Share

0.11 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

5.91 %

(as of Nov 21)

Historic

Pain - Market Share

2.90 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

33.90 %

(as of Dec 24)

Source/Historic

Powder Market Share(Nycil)

5.57 %

(as of Nov 21)

Historic

Respiratory - Market Share

5.37 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

1.58 %

(as of May 19)

Historic

Stomatological - Market Share

0.06 %

(as of Nov 21)

Historic

Urology - Market Share

0 %

(as of Jun 22)

Historic

Vaccines - Market Share

1.40 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up - India Formulations

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)

Zydus Lifesciences Ltd.

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
US DMF Filings (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Zydus Lifesciences	889.65	19.63	88,825	74.99	17.96	22	19.46
Lupin	1,999.8	27.34	89,716	46.92	14.24	17.99	13.4
Dr. Reddy's Lab	1,225.2	18.08	1,02,237	26.64	19.89	26.07	19.74
Mankind Pharma	2,520.8	51.55	1,05,236	72.7	23.9	24.78	20.43
Torrent Pharma	3,291.8	57.44	1,09,770	68.31	7.8	28.82	24.16
Aurobindo Pharma	1,203.8	19.83	69,214	51.82	8.53	15.41	10.63
Abbott India	31,415	46.26	65,429	74.99	11.54	42.51	32.48
Alkem Laboratories	5,366	29.21	62,901	55.13	1.52	22.42	17.41

Brands

EverYuth

Nutralite

SugarFree

Corporate Actions

Consolidated DividendSplit

DATE

DETAILS

2024, Jul 26

Dividend Dividend of Rs.3 per share

2023, Jul 28

Dividend Dividend of Rs.6 per share

2022, Jul 28

Dividend Dividend of Rs.2.5 per share

2021, Jul 28

Dividend Dividend of Rs.3.5 per share

2020, Mar 23

Dividend Dividend of Rs.3.5 per share

Suppliers

Time Technoplast Ltd.
EPL Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Vidhi Specialty Food Ingredients Ltd.
Gulshan Polyols Ltd.

FAQs on Zydus Lifesciences Ltd. Business

What does Zydus Lifesciences do?

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an integrated pharmaceutical company based in India. They cover the entire value chain from research to distribution, specializing in API and human formulations.

Who are the competitors of Zydus Lifesciences?

Zydus Lifesciences major competitors are Lupin, Dr. Reddy's Lab, Mankind Pharma, Torrent Pharma, Aurobindo Pharma, Abbott India, Alkem Laboratories.
Market Cap of Zydus Lifesciences is ₹88,825 Crs.
While the median market cap of its peers are ₹89,716 Crs.

Is Zydus Lifesciences financially stable compared to its competitors?

Zydus Lifesciences seems to be less financially stable compared to its competitors.
Altman Z score of Zydus Lifesciences is 9.52 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar	Jun Dec
Investor Presentation	Mar May	Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar May Jun Aug Sep Dec	Jun Sep Dec	Mar Jun Dec	Mar Dec	Mar Dec	Mar Jun Sep Dec	Mar Sep Dec	Mar	Mar		Mar	Mar
Conference Call		Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar	Mar Jun Sep	Mar Jun Sep	Mar Jun Dec	Mar Dec	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep	Mar Jun Sep
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Zydus Lifesciences Ltd.

View the discussion on ValuePickr - ValuePickr

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd.

About

Timeline

Company Timeline

11 Yes

2 Neutral

4 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Retail Holding

Promoter Holding

Revenue Recognition

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Debt

ROCE Strength

Balance Sheet Strength

Current vs Historic Valuation

Sales Growth

Margin Stability

Product Wise Break-Up

UNLOCK PREMIUM

Segment Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up - India Formulations

UNLOCK PREMIUM

Operating Profit Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

Number of ANDA's Filed in USA (.)

Number of ANDA's Filed in USA (.)

What does Zydus Lifesciences do?

Who are the competitors of Zydus Lifesciences?

Is Zydus Lifesciences financially stable compared to its competitors?

SIGN UP FOR FREE